Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Vet Intern Med ; 29(1): 200-6, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25619515

ABSTRACT

BACKGROUND: Long-term treatment of cats with ionized hypercalcemia using alendronate has not been evaluated. HYPOTHESIS/OBJECTIVES: Alendronate is well tolerated in treatment of ionized hypercalcemia in cats. ANIMALS: A total of 12 cats with ionized hypercalcemia. METHODS: Prospective study of 12 cats with ionized hypercalcemia of idiopathic origin was identified by telephone and email communication with a convenience sample of consulting veterinarians. Cats were treated with alendronate at a dose of 5-20 mg per feline PO q7d. Serum ionized calcium concentration (iCa) was measured before beginning treatment with alendronate, and after 1, 3, and 6 months of treatment. Alendronate dosage was adjusted according to iCa. Evaluation included physical examination, CBC, biochemistry profile, and diagnostic imaging. The owners and referring veterinarians were questioned about any observed adverse effects. The Wilcoxon matched-pairs signed rank test was used to compare baseline iCa to iCa at different time periods. RESULTS: Alendronate treatment resulted in a decrease in iCa in all 12 cats. The median percentage change in iCa was -13.2%, -15.9%, and -18.1% (range, -29.6 to +7.6; -30.5 to -1.9; -45.8 to +1.5%) at the 1, 3, and 6 month time points, respectively. Baseline iCa was significantly different from 1 month (P = .0042), 3 months (P = .0005), and 6 months (P = .0015). No adverse effects were reported for any of the cats. CONCLUSIONS AND CLINICAL IMPORTANCE: Alendronate was well tolerated and decreased iCa in most cats for the 6-month period of observation.


Subject(s)
Alendronate/therapeutic use , Cat Diseases/drug therapy , Hypercalcemia/veterinary , Administration, Oral , Alendronate/administration & dosage , Animals , Calcium/blood , Cats , Drug Administration Schedule , Hypercalcemia/drug therapy
2.
J Vet Intern Med ; 26(2): 334-40, 2012.
Article in English | MEDLINE | ID: mdl-22295898

ABSTRACT

BACKGROUND: Status epilepticus (SE) and acute repetitive seizures (ARS) are common canine neurologic emergencies. No evidence-based studies are available to guide treatment in veterinary patients. Parenteral levetiracetam (LEV) has many favorable properties for the emergency treatment of seizures, but its safety and efficacy in dogs for SE and ARS are unknown. HYPOTHESIS: Intravenous LEV is superior to placebo in controlling seizures in dogs with SE or ARS after treatment with IV diazepam. ANIMALS: Nineteen client-owned dogs admitted for SE or ARS. METHODS: Randomized, placebo-controlled, double-masked study. Dogs with SE or ARS were randomized to receive IV LEV (30 or 60 mg/kg using an adaptive dose-escalation approach) or placebo, in addition to standard of care treatment. They were monitored for at least 24 hours after admission for additional seizures. RESULTS: The responder rate (defined as dogs with no additional seizures after administration of the study medication) after LEV was 56% compared with 10% for placebo (P = .06). Dogs in the placebo group required significantly more boluses of diazepam compared with the LEV group (P < .03). Seizure etiologies identified were idiopathic epilepsy (n = 10), inflammatory central nervous system disease (n = 4), intracranial neoplasia (n = 2), hepatic encephalopathy (n = 1), and 2 dogs had no cause determined. No serious adverse effects were attributable to LEV administration. CONCLUSIONS AND CLINICAL IMPORTANCE: LEV was safe and potentially effective for the treatment of SE and ARS in these client-owned dogs. Larger, controlled clinical trials are needed to confirm this preliminary observation.


Subject(s)
Anticonvulsants/administration & dosage , Dog Diseases/drug therapy , Piracetam/analogs & derivatives , Seizures/veterinary , Status Epilepticus/veterinary , Animals , Anticonvulsants/adverse effects , Anticonvulsants/blood , Diazepam/administration & dosage , Dog Diseases/blood , Dogs , Double-Blind Method , Female , Half-Life , Injections, Intravenous/veterinary , Levetiracetam , Male , Pilot Projects , Piracetam/administration & dosage , Piracetam/adverse effects , Piracetam/blood , Seizures/blood , Seizures/drug therapy , Statistics, Nonparametric , Status Epilepticus/blood , Status Epilepticus/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...